China Drafts Export Rules to Block Foreign Acquisitions of Core Biotech Platforms
Beijing has released a draft policy to restrict the export of key biopharmaceutical technologies, specifically targeting foreign acquisitions of cell and gene therapy, siRNA, and pathogen gain-of-function platforms. While the move aims to protect proprietary assets, it explicitly excludes common out-licensing agreements, preserving the majority of current cross-border deal structures.